LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 76

Search options

  1. Article ; Online: Molecular and immunological mechanisms of clonal evolution in multiple myeloma.

    Forster, Stefan / Radpour, Ramin / Ochsenbein, Adrian F

    Frontiers in immunology

    2023  Volume 14, Page(s) 1243997

    Abstract: Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of clonal plasma cells in the bone marrow (BM). It is known that early genetic mutations in post-germinal center B/plasma cells are the cause of myelomagenesis. The ... ...

    Abstract Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of clonal plasma cells in the bone marrow (BM). It is known that early genetic mutations in post-germinal center B/plasma cells are the cause of myelomagenesis. The acquisition of additional chromosomal abnormalities and distinct mutations further promote the outgrowth of malignant plasma cell populations that are resistant to conventional treatments, finally resulting in relapsed and therapy-refractory terminal stages of MM. In addition, myeloma cells are supported by autocrine signaling pathways and the tumor microenvironment (TME), which consists of diverse cell types such as stromal cells, immune cells, and components of the extracellular matrix. The TME provides essential signals and stimuli that induce proliferation and/or prevent apoptosis. In particular, the molecular pathways by which MM cells interact with the TME are crucial for the development of MM. To generate successful therapies and prevent MM recurrence, a thorough understanding of the molecular mechanisms that drive MM progression and therapy resistance is essential. In this review, we summarize key mechanisms that promote myelomagenesis and drive the clonal expansion in the course of MM progression such as autocrine signaling cascades, as well as direct and indirect interactions between the TME and malignant plasma cells. In addition, we highlight drug-resistance mechanisms and emerging therapies that are currently tested in clinical trials to overcome therapy-refractory MM stages.
    MeSH term(s) Humans ; Multiple Myeloma/therapy ; Multiple Myeloma/drug therapy ; Plasma Cells/metabolism ; Bone Marrow/metabolism ; Hematologic Neoplasms ; Clonal Evolution/genetics ; Tumor Microenvironment/genetics
    Language English
    Publishing date 2023-09-06
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2023.1243997
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Genetic Alterations Impact Immune Microenvironment Interactions in Follicular Lymphoma.

    Riether, Carsten / Ochsenbein, Adrian F

    Cancer cell

    2020  Volume 37, Issue 5, Page(s) 621–622

    Abstract: Interactions between germinal center B cells and immune cells in the microenvironment can play integral roles in transformation and growth of follicular lymphoma (FL). Three recent studies, two in this issue of Cancer Cell and one in Cell Reports, ... ...

    Abstract Interactions between germinal center B cells and immune cells in the microenvironment can play integral roles in transformation and growth of follicular lymphoma (FL). Three recent studies, two in this issue of Cancer Cell and one in Cell Reports, elucidate how genetic alterations in CTSS and EZH2 impact these interactions, with implications for FL immunotherapy.
    MeSH term(s) Cathepsins ; Germinal Center ; Humans ; Lymphoma, Follicular/genetics ; Tumor Microenvironment/genetics
    Chemical Substances Cathepsins (EC 3.4.-) ; cathepsin S (EC 3.4.22.27)
    Language English
    Publishing date 2020-05-12
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 2078448-X
    ISSN 1878-3686 ; 1535-6108
    ISSN (online) 1878-3686
    ISSN 1535-6108
    DOI 10.1016/j.ccell.2020.04.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Epigenetic Silencing of Immune-Checkpoint Receptors in Bone Marrow- Infiltrating T Cells in Acute Myeloid Leukemia.

    Radpour, Ramin / Stucki, Miriam / Riether, Carsten / Ochsenbein, Adrian F

    Frontiers in oncology

    2021  Volume 11, Page(s) 663406

    Abstract: Background: Immune-checkpoint (IC) inhibitors have revolutionized the treatment of multiple solid tumors and defined lymphomas, but they are largely ineffective in acute myeloid leukemia (AML). The reason why especially PD1/PD-L1 blocking agents are not ...

    Abstract Background: Immune-checkpoint (IC) inhibitors have revolutionized the treatment of multiple solid tumors and defined lymphomas, but they are largely ineffective in acute myeloid leukemia (AML). The reason why especially PD1/PD-L1 blocking agents are not efficacious is not well-understood but it may be due to the contribution of different IC ligand/receptor interactions that determine the function of T cells in AML.
    Methods: To analyze the interactions of IC ligands and receptors in AML, we performed a comprehensive transcriptomic analysis of FACS-purified leukemia stem/progenitor cells and paired bone marrow (BM)-infiltrating CD4
    Results: We observed that IC ligands and receptors were mainly upregulated in leukemia stem cells. The gene expression of activating IC ligands and receptors correlated with improved prognosis and vice versa. In contrast, the majority of IC receptor genes were downregulated in BM-infiltrating CD8
    Conclusions: Our results suggest that CD8
    Language English
    Publishing date 2021-05-04
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2021.663406
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: IL-33-ST2 signaling promotes stemness in subtypes of myeloid leukemia cells through the Wnt and Notch pathways.

    Naef, Pascal / Radpour, Ramin / Jaeger-Ruckstuhl, Carla A / Bodmer, Nils / Baerlocher, Gabriela M / Doehner, Hartmut / Doehner, Konstanze / Riether, Carsten / Ochsenbein, Adrian F

    Science signaling

    2023  Volume 16, Issue 800, Page(s) eadd7705

    Abstract: Cell stemness is characterized by quiescence, pluripotency, and long-term self-renewal capacity. Therapy-resistant leukemic stem cells (LSCs) are the primary cause of relapse in patients with chronic and acute myeloid leukemia (CML and AML). However, the ...

    Abstract Cell stemness is characterized by quiescence, pluripotency, and long-term self-renewal capacity. Therapy-resistant leukemic stem cells (LSCs) are the primary cause of relapse in patients with chronic and acute myeloid leukemia (CML and AML). However, the same signaling pathways frequently support stemness in both LSCs and normal hematopoietic stem cells (HSCs), making LSCs difficult to therapeutically target. In cell lines and patient samples, we found that interleukin-33 (IL-33) signaling promoted stemness only in leukemia cells in a subtype-specific manner. The IL-33 receptor ST2 was abundant on the surfaces of CD34
    MeSH term(s) Animals ; Mice ; Interleukin-1 Receptor-Like 1 Protein ; Interleukin-33/genetics ; Leukemia, Myeloid ; NF-kappa B ; Wnt Signaling Pathway
    Chemical Substances Interleukin-1 Receptor-Like 1 Protein ; Interleukin-33 ; NF-kappa B ; IL1RL1 protein, human ; IL33 protein, human
    Language English
    Publishing date 2023-08-29
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2417226-1
    ISSN 1937-9145 ; 1945-0877
    ISSN (online) 1937-9145
    ISSN 1945-0877
    DOI 10.1126/scisignal.add7705
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: CD8

    Radpour, Ramin / Riether, Carsten / Simillion, Cedric / Höpner, Sabine / Bruggmann, Rémy / Ochsenbein, Adrian F

    Leukemia

    2019  Volume 33, Issue 10, Page(s) 2379–2392

    Abstract: ... ...

    Abstract CD8
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Bone Marrow/immunology ; CD8-Positive T-Lymphocytes/immunology ; Cell Proliferation/physiology ; Cytokines/immunology ; Humans ; Interleukin-3/immunology ; Leukemia, Myeloid, Acute/immunology ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; Stem Cells/immunology ; Young Adult
    Chemical Substances Cytokines ; Interleukin-3
    Language English
    Publishing date 2019-03-15
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 807030-1
    ISSN 1476-5551 ; 0887-6924
    ISSN (online) 1476-5551
    ISSN 0887-6924
    DOI 10.1038/s41375-019-0441-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Tnfrsf4-expressing regulatory T cells promote immune escape of chronic myeloid leukemia stem cells.

    Hinterbrandner, Magdalena / Rubino, Viviana / Stoll, Carina / Forster, Stefan / Schnüriger, Noah / Radpour, Ramin / Baerlocher, Gabriela M / Ochsenbein, Adrian F / Riether, Carsten

    JCI insight

    2021  Volume 6, Issue 23

    Abstract: Leukemia stem cells (LSCs) promote the disease and seem resistant to therapy and immune control. Why LSCs are selectively resistant against elimination by CD8+ cytotoxic T cells (CTLs) is still unknown. In this study, we demonstrate that LSCs in chronic ... ...

    Abstract Leukemia stem cells (LSCs) promote the disease and seem resistant to therapy and immune control. Why LSCs are selectively resistant against elimination by CD8+ cytotoxic T cells (CTLs) is still unknown. In this study, we demonstrate that LSCs in chronic myeloid leukemia (CML) can be recognized and killed by CD8+ CTLs in vitro. However, Tregs, which preferentially localized close to CD8+ CTLs in CML BM, protected LSCs from MHC class I-dependent CD8+ CTL-mediated elimination in vivo. BM Tregs in CML were characterized by the selective expression of tumor necrosis factor receptor 4 (Tnfrsf4). Stimulation of Tnfrsf4 signaling did not deplete Tregs but reduced the capacity of Tregs to protect LSCs from CD8+ CTL-mediated killing. In the BM of newly diagnosed CML patients, TNFRSF4 mRNA levels were significantly increased and correlated with the expression of the Treg-restricted transcription factor FOXP3. Overall, these results identify Tregs as key regulators of immune escape of LSCs and TNFRSF4 as a potential target to reduce the function of Tregs and boost antileukemic immunity in CML.
    MeSH term(s) Animals ; Chronic Disease ; Female ; Humans ; Immunotherapy/methods ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/immunology ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology ; Male ; Mice ; Receptors, OX40/metabolism ; T-Lymphocytes, Regulatory/immunology ; Tumor Escape/immunology
    Chemical Substances Receptors, OX40 ; TNFRSF4 protein, human
    Language English
    Publishing date 2021-12-08
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2379-3708
    ISSN (online) 2379-3708
    DOI 10.1172/jci.insight.151797
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma.

    Yang, Haitang / Gao, Yanyun / Xu, Duo / Xu, Ke / Liang, Shun-Qing / Yang, Zhang / Scherz, Amina / Hall, Sean R R / Forster, Stefan / Berezowska, Sabina / Yao, Feng / Ochsenbein, Adrian F / Marti, Thomas M / Kocher, Gregor J / Schmid, Ralph A / Dorn, Patrick / Peng, Ren-Wang

    Cell death discovery

    2023  Volume 9, Issue 1, Page(s) 55

    Abstract: Malignant pleural mesothelioma (MPM) is a lethal malignancy etiologically caused by asbestos exposure, for which there are few effective treatment options. Although asbestos carcinogenesis is associated with reactive oxygen species (ROS), the bona fide ... ...

    Abstract Malignant pleural mesothelioma (MPM) is a lethal malignancy etiologically caused by asbestos exposure, for which there are few effective treatment options. Although asbestos carcinogenesis is associated with reactive oxygen species (ROS), the bona fide oncogenic signaling pathways that regulate ROS homeostasis and bypass ROS-evoked apoptosis in MPM are poorly understood. In this study, we demonstrate that the mitogen-activated protein kinase (MAPK) pathway RAS-RAF-MEK-ERK is hyperactive and a molecular driver of MPM, independent of histological subtypes and genetic heterogeneity. Suppression of MAPK signaling by clinically approved MEK inhibitors (MEKi) elicits PARP1 to protect MPM cells from the cytotoxic effects of MAPK pathway blockage. Mechanistically, MEKi induces impairment of homologous recombination (HR) repair proficiency and mitochondrial metabolic activity, which is counterbalanced by pleiotropic PARP1. Consequently, the combination of MEK with PARP inhibitors enhances apoptotic cell death in vitro and in vivo that occurs through coordinated upregulation of cytotoxic ROS in MPM cells, suggesting a mechanism-based, readily translatable strategy to treat this daunting disease. Collectively, our studies uncover a previously unrecognized scenario that hyperactivation of the MAPK pathway is an essential feature of MPM and provide unprecedented evidence that MAPK signaling cooperates with PARP1 to homeostatically maintain ROS levels and escape ROS-mediated apoptosis.
    Language English
    Publishing date 2023-02-10
    Publishing country United States
    Document type Journal Article
    ISSN 2058-7716
    ISSN 2058-7716
    DOI 10.1038/s41420-023-01307-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities.

    Haas, Quentin / Markov, Nikita / Muerner, Lukas / Rubino, Viviana / Benjak, Andrej / Haubitz, Monika / Baerlocher, Gabriela M / Ng, Charlotte K Y / Münz, Christian / Riether, Carsten / Ochsenbein, Adrian F / Simon, Hans-Uwe / von Gunten, Stephan

    Frontiers in immunology

    2022  Volume 13, Page(s) 996746

    Abstract: While inhibitory Siglec receptors are known to regulate myeloid cells, less is known about their expression and function in lymphocytes subsets. Here we identified Siglec-7 as a glyco-immune checkpoint expressed on non-exhausted effector memory CD8+ T ... ...

    Abstract While inhibitory Siglec receptors are known to regulate myeloid cells, less is known about their expression and function in lymphocytes subsets. Here we identified Siglec-7 as a glyco-immune checkpoint expressed on non-exhausted effector memory CD8+ T cells that exhibit high functional and metabolic capacities. Seahorse analysis revealed higher basal respiration and glycolysis levels of Siglec-7
    MeSH term(s) Actins ; Antigens, Differentiation, Myelomonocytic ; CD8-Positive T-Lymphocytes ; Humans ; Lectins ; Leukemia, Myeloid, Acute ; Sialic Acid Binding Immunoglobulin-like Lectins
    Chemical Substances Actins ; Antigens, Differentiation, Myelomonocytic ; Lectins ; SIGLEC7 protein, human ; Sialic Acid Binding Immunoglobulin-like Lectins
    Language English
    Publishing date 2022-09-23
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2022.996746
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.

    Pabst, Thomas / Vey, Norbert / Adès, Lionel / Bacher, Ulrike / Bargetzi, Mario / Fung, Samson / Gaidano, Gianluca / Gandini, Domenica / Hultberg, Anna / Johnson, Amy / Ma, Xuewen / Müller, Rouven / Nottage, Kerri / Papayannidis, Cristina / Recher, Christian / Riether, Carsten / Shah, Priya / Tryon, Jeffrey / Xiu, Liang /
    Ochsenbein, Adrian F

    Haematologica

    2023  Volume 108, Issue 7, Page(s) 1793–1802

    Abstract: Cusatuzumab is a high-affinity, anti-CD70 monoclonal antibody under investigation in acute myeloid leukemia (AML). This two-part, open-label, multicenter, phase I/II trial evaluated cusatuzumab plus azacitidine in patients with newly diagnosed AML ... ...

    Abstract Cusatuzumab is a high-affinity, anti-CD70 monoclonal antibody under investigation in acute myeloid leukemia (AML). This two-part, open-label, multicenter, phase I/II trial evaluated cusatuzumab plus azacitidine in patients with newly diagnosed AML ineligible for intensive chemotherapy. Patients received a single dose of cusatuzumab at one of four dose levels (1, 3, 10, or 20 mg/kg) 14 days before starting combination therapy. In phase I dose escalation, cusatuzumab was then administered on days 3 and 17, in combination with azacitidine (75 mg/m2) on days 1-7, every 28 days. The primary objective in phase I was to determine the recommended phase II dose (RP2D) of cusatuzumab plus azacitidine. The primary objective in phase II was efficacy at the RP2D (selected as 10 mg/kg). Thirty-eight patients were enrolled: 12 in phase I (three per dose level; four with European LeukemiaNet 2017 adverse risk) and 26 in phase II (21 with adverse risk). An objective response (≥partial remission) was achieved by 19/38 patients (including 8/26 in phase II); 14/38 achieved complete remission. Eleven patients (37.9%) achieved an objective response among the 29 patients in phase I and phase II treated at the RP2D. At a median follow-up of 10.9 months, median duration of first response was 4.5 months and median overall survival was 11.5 months. The most common treatment-emergent adverse events were infections (84.2%) and hematologic toxicities (78.9%). Seven patients (18.4%) reported infusion-related reactions, including two with grade 3 events. Thus, cusatuzumab/azacitidine appears generally well tolerated and shows preliminary efficacy in this setting. Investigation of cusatuzumab combined with current standard-of-care therapy, comprising venetoclax and azacitidine, is ongoing.
    MeSH term(s) Humans ; Azacitidine/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Agents/therapeutic use ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/drug therapy ; Antibodies, Monoclonal/therapeutic use
    Chemical Substances Azacitidine (M801H13NRU) ; Antineoplastic Agents ; Antibodies, Monoclonal
    Language English
    Publishing date 2023-07-01
    Publishing country Italy
    Document type Clinical Trial, Phase II ; Clinical Trial, Phase I ; Multicenter Study ; Journal Article
    ZDB-ID 2333-4
    ISSN 1592-8721 ; 0017-6567 ; 0390-6078
    ISSN (online) 1592-8721
    ISSN 0017-6567 ; 0390-6078
    DOI 10.3324/haematol.2022.281563
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Splenic red pulp macrophages provide a niche for CML stem cells and induce therapy resistance.

    Bührer, Elias D / Amrein, Michael A / Forster, Stefan / Isringhausen, Stephan / Schürch, Christian M / Bhate, Salil S / Brodie, Tess / Zindel, Joel / Stroka, Deborah / Sayed, Mohamad Al / Nombela-Arrieta, César / Radpour, Ramin / Riether, Carsten / Ochsenbein, Adrian F

    Leukemia

    2022  Volume 36, Issue 11, Page(s) 2634–2646

    Abstract: Disease progression and relapse of chronic myeloid leukemia (CML) are caused by therapy resistant leukemia stem cells (LSCs), and cure relies on their eradication. The microenvironment in the bone marrow (BM) is known to contribute to LSC maintenance and ...

    Abstract Disease progression and relapse of chronic myeloid leukemia (CML) are caused by therapy resistant leukemia stem cells (LSCs), and cure relies on their eradication. The microenvironment in the bone marrow (BM) is known to contribute to LSC maintenance and resistance. Although leukemic infiltration of the spleen is a hallmark of CML, it is unknown whether spleen cells form a niche that maintains LSCs. Here, we demonstrate that LSCs preferentially accumulate in the spleen and contribute to disease progression. Spleen LSCs were located in the red pulp close to red pulp macrophages (RPM) in CML patients and in a murine CML model. Pharmacologic and genetic depletion of RPM reduced LSCs and decreased their cell cycling activity in the spleen. Gene expression analysis revealed enriched stemness and decreased myeloid lineage differentiation in spleen leukemic stem and progenitor cells (LSPCs). These results demonstrate that splenic RPM form a niche that maintains CML LSCs in a quiescent state, resulting in disease progression and resistance to therapy.
    MeSH term(s) Humans ; Mice ; Animals ; Spleen ; Neoplastic Stem Cells/metabolism ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Leukemia, Myeloid/genetics ; Macrophages/metabolism ; Disease Progression ; Tumor Microenvironment
    Language English
    Publishing date 2022-09-26
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 807030-1
    ISSN 1476-5551 ; 0887-6924
    ISSN (online) 1476-5551
    ISSN 0887-6924
    DOI 10.1038/s41375-022-01682-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top